Invitrx licenses fat-derived stem cell products to Bioheart

09/25/2013 | Pharmaceutical Business Review Online

Bioheart, which specializes in developing autologous cell treatments for heart damage and severe peripheral vascular disease, secured the rights to use Invitrx Therapeutics' adipose-based stem cell products under a licensing agreement. Bioheart could release preliminary results from an early-stage clinical study soon.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA